Hoffmann La Roche patents expiration
1. Boniva patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US6143326 | HOFFMANN LA ROCHE | Oral pharmaceutical preparation containing ibandronat |
Apr, 2017
(7 years ago) | |
| US6294196 | HOFFMANN LA ROCHE | Pharmaceutical composition containing diphosphonic acid or salt thereof |
Oct, 2019
(4 years ago) | |
| US7410957 | HOFFMANN LA ROCHE | Method of treatment using bisphosphonic acid |
May, 2023
(11 months ago) | |
| US7718634 | HOFFMANN LA ROCHE | Method of treatment using bisphosphonic acid |
May, 2023
(11 months ago) | |
| US7192938 | HOFFMANN LA ROCHE | Method of treatment using bisphosphonic acid |
May, 2023
(11 months ago) | |
Drugs and Companies using IBANDRONATE SODIUM ingredient
Market Authorisation Date: 16 May, 2003
Treatment: Treatment and prevention of osteoporosis; Treatment and prevention of osteoporosis in postmenopausal women by once-monthly oral administration of ibandronate sodium monohydrate equivalent to 150mg of ...
Dosage: TABLET;ORAL
BONIVA family patents
2. Fortovase patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US6008228 | HOFFMANN LA ROCHE | Pharmaceutical compositions containing proteinase inhibitors |
Jun, 2015
(8 years ago) | |
|
US6008228 (Pediatric) | HOFFMANN LA ROCHE | Pharmaceutical compositions containing proteinase inhibitors |
Dec, 2015
(8 years ago) | |
| US6352717 | HOFFMANN LA ROCHE | Process for encapsulating shear sensitive fill masses into capsules and capsules containing shear sensitive fill masses |
Nov, 2019
(4 years ago) | |
|
US6352717 (Pediatric) | HOFFMANN LA ROCHE | Process for encapsulating shear sensitive fill masses into capsules and capsules containing shear sensitive fill masses |
May, 2020
(3 years ago) | |
Drugs and Companies using SAQUINAVIR ingredient
Market Authorisation Date: 07 November, 1997
Treatment: NA
Dosage: CAPSULE;ORAL
FORTOVASE family patents
3. Zelboraf patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US8143271 | HOFFMANN LA ROCHE | NA |
Jun, 2026
(2 years from now) | |
| US7504509 | HOFFMANN LA ROCHE | Compounds and methods for development of Ret modulators |
Oct, 2026
(2 years from now) | |
| US7863288 | HOFFMANN LA ROCHE | NA |
Jun, 2029
(5 years from now) | |
| US8741920 | HOFFMANN LA ROCHE | Process for the manufacture of pharmaceutically active compounds |
Jul, 2030
(6 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8470818 | HOFFMANN LA ROCHE | NA |
Aug, 2026
(2 years from now) | |
| US9447089 | HOFFMANN LA ROCHE | Compositions and uses thereof |
Jun, 2032
(8 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| Orphan Drug Exclusivity(ODE-158) | Nov 06, 2024 |
| M(M-184) | Aug 31, 2019 |
| New Indication(I-757) | Nov 06, 2020 |
| Orphan Drug Exclusivity(ODE-13) | Aug 17, 2018 |
| New Chemical Entity Exclusivity(NCE) | Aug 17, 2016 |
| Orphan Drug Exclusivity(ODE) | Aug 17, 2018 |
Drugs and Companies using VEMURAFENIB ingredient
NCE-1 date: 18 August, 2015
Market Authorisation Date: 17 August, 2011
Treatment: Treatment of patients with unresectable or metastatic melanoma with brafv600e mutation as detected by an fda approved test
Dosage: TABLET;ORAL
ZELBORAF family patents